0.86

8.56% 0.0678

Citius Oncology Inc (CTOR)

Overview News Price History Discussions Forecast

Citius Oncology Inc stock is traded at $0.86, with a volume of 54,510. It is up +8.56% in the last 24 hours and up +30.30% over the past month. Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.

Previous Close:

$0.7922

Open:

$0.7666

24h Volume:

54,510

Relative Volume:

0.73

Market Cap:

$90.95M

Revenue:

$5.61M

Net Income/Loss:

$-42.51M

P/E Ratio:

-1.8455

EPS:

-0.466

Net Cash Flow:

$-16.86M

1W Performance:

+10.88%

1M Performance:

+30.30%

6M Performance:

-21.10%

1Y Performance:

-54.01%

1-Day Range:

$0.7501

$0.8816

1-Week Range:

$0.7245

$0.8816

52-Week Range:

$0.4912

$2.25

Citius Oncology Inc Stock (CTOR) Company Profile

Name

Citius Oncology Inc

Sector

Healthcare (1074)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

(908) 967-6677

Address

11 COMMERCE DRIVE, CRANFORD

Employee

Twitter

Next Earnings Date

2026-08-18

Latest SEC Filings

CTOR's Discussions on Twitter

Compare CTOR vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTOR Citius Oncology Inc	0.86	80.28M	5.61M	-42.51M	-16.86M	-0.466
TAK Takeda Pharmaceutical Co Adr	18.45	57.90B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.36	42.89B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.60	43.41B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	75.81	31.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	487.61	22.35B	3.17B	1.29B	1.01B	27.09

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-23-25	Upgrade	Maxim Group	Hold → Buy
Nov-27-24	Initiated	Maxim Group	Buy

Citius Oncology Inc Stock (CTOR) Latest News

Aug 20, 2026

Armistice Capital Expands Citius Oncology (CTOR) Stake Despite Distress Signals - GuruFocus

Aug 20, 2026

Citius (CTOR) Quarterly Results: Reported EPS Misses Expectations in the Reported Period; After Results: The Market Price Advances 6.97% on the DayForward Guidance Trends - vinanet.vn

Aug 20, 2026

Aug 18, 2026

Citius Oncology Shares Slide 10% After Fiscal Q3 Revenue Misses Estimates Despite LYMPHIR Launch Gains - dars.gov.et

Aug 18, 2026

Aug 17, 2026

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - Yahoo Finance

Aug 17, 2026

Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com Australia

Aug 17, 2026

Aug 15, 2026

CTOR Q2 2026 Earnings: Pre-Revenue Loss Misses Badly, Yet Shares Jump 10%EBITDA Analysis - vinanet.vn

Aug 15, 2026

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - simplywall.st

Aug 15, 2026

Aug 14, 2026

Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart

Aug 14, 2026

Citius Oncology Posts First Revenue from LYMPHIR Launch as Institutional Demand Surges 31% - Minichart

Aug 14, 2026

Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat

Aug 14, 2026

Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan

Aug 14, 2026

Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade

Aug 14, 2026

Citius Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI

Aug 14, 2026

CTOR: LYMPHIR launch drove $7.1M revenue and 31% sequential vial order growth, with broad payer access - TradingView

Aug 14, 2026

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan

Aug 14, 2026

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire

Aug 14, 2026

Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneInverse ETF Flow - vinanet.vn

Aug 14, 2026

Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake - Stock Titan

Aug 14, 2026

Aug 13, 2026

Citius Oncology appoints independent director Peri to board of directors - ROI-NJ

Aug 13, 2026

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia

Aug 13, 2026

Aug 12, 2026

People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz

Aug 12, 2026

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar

Aug 12, 2026

Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union

Aug 12, 2026

Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com South Africa

Aug 12, 2026

Citius Oncology adds independent director to expanded board - TipRanks

Aug 12, 2026

Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz

Aug 12, 2026

Citius Oncology appoints Jonathan Peri to board of directors - Investing.com

Aug 12, 2026

Aug 11, 2026

Citius Oncology (CTOR) Expected to Announce Earnings on Tuesday - MarketBeat

Aug 11, 2026

Aug 09, 2026